Search

Displaying results 1741 - 1750 of 10000 in total
  1. Drug

    Metolazone

    go.drugbank.com/drugs/DB00524
    ApprovedInvestigational

    A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.

    Synonyms: 2-Methyl-3-o-tolyl-6-sulfamyl-7-chloro-1,2,3,4-tetrahydro-4-quinazolinone, 7-Chloro-1,2,3,4-tetrahydro-2-methyl-4-oxo-3-o-tolyl-6-quinazolinesulfonamideCategories: combinations of sulfonamides, Non Potassium Sparing Diuretics
  2. Drug

    Segesterone acetate

    go.drugbank.com/drugs/DB14583
    Approved

    On August 10, 2018, Annovera™ containing segesterone acetate and [ethinyl estradiol] was granted approval by the U.S. … Due to its rapid hepatic metabolism, segesterone acetate must be administered parenterally [A37090].

  3. Drug

    Upanovimab

    go.drugbank.com/drugs/DB16505
    Investigational

    Upanovimab (SCTA01) was under investigation in clinical trials (NCT04683328, NCT04644185, NCT04709328 and NCT05156645) to evaluate its safety and efficacy in patients with severe COVID-19

  4. Drug

    Acetohexamide

    go.drugbank.com/drugs/DB00414
    ApprovedWithdrawn

    A sulfonylurea hypoglycemic agent that is metabolized in the liver to 1-hydrohexamide. Acetohexamide has been discontinued in the US market.

    Categories: combinations of sulfonamides, Drugs Used in DiabetesSynonyms: N-(p-Acetylphenylsulfonyl)-N'-cyclohexylurea, 1-[(4-acetylbenzene)sulfonyl]-3-cyclohexylurea 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
  5. Drug

    Exemestane

    go.drugbank.com/drugs/DB00990
    ApprovedInvestigational

    It irreversibly binds to the active site of the enzyme resulting in permanent inhibition. … Exemestane is an oral steroidal aromatase inhibitor used in the adjuvant treatment of hormonally-responsive (also called hormone-receptor-positive, estrogen-responsive) breast cancer in postmenopausal

  6. Drug

    Epoprostenol

    go.drugbank.com/drugs/DB01240
    ApprovedInvestigational

    It is biosynthesized enzymatically from prostaglandin endoperoxides in human vascular tissue. The sodium salt has been also used to treat primary pulmonary hypertension.

  7. Indication

    Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

    go.drugbank.com/conditions/DBCOND0069581
    Drugs: Ruxolitinib
    Synonyms: Thrombocythemia Myelofibrosis (PET-MF), Post-essential Thrombocythemia Myelofibrosis (PET-MF)
  8. Drug

    Letrozole

    go.drugbank.com/drugs/DB01006
    ApprovedInvestigational

    [A190546] Letrozole was granted FDA approval on 25 July 1997.[L11623] … Letrozole, or CGS 20267, is an oral non-steroidal type II aromatase inhibitor first described in the literature in 1990.

    Products: SOLESTRASA-IN
  9. Drug

    Magnesium gluconate

    go.drugbank.com/drugs/DB13749
    ApprovedWithdrawn

    In addition, it has been studied for its effects on premature uterine contractions [A32808]. … Magnesium gluconate is a magnesium salt of gluconate. It demonstrates the highest oral bioavailability of magnesium salts [L2608] and is used as a mineral supplement.

    Mixtures: Swiss One Timed Release TabSynonyms: Magnesium D-gluconate (1:2) hydrate, Magnesium D-gluconate (1:2) dihydrate
  10. Drug

    Ranibizumab

    go.drugbank.com/drugs/DB01270
    ApprovedInvestigational

    of age-related macular degeneration. … BYOOVIZ, a biosimilar of LUCENTIS, was approved by Health Canada in March 2022, making it the first and only biosimilar drug of ranibizumab available in Canada.

    Products: LUCENTIS 10 MG/ML SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE, LUCENTIS SOLUTION FOR INJECTION IN PRE-FILLED SYRINGE 1.65mg/0.165ml